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CASE REPORT
Introduction
Hepatic hemangiomas are soft tumors that usually do not compress bile ducts, the portal vein, 
or the inferior vena cava. In rare cases, these can be large (giant hemangioma) and eventually 
compress the biliary or vascular structures [1]. However, no cases have been reported in the 
literature in which hepatic lobar atrophy and portal vein thrombosis developed as a result of hepatic 
hemangioma compression. Isolated diffuse hepatic hemangiomatosis without extrahepatic lesions is 
extremely rare in adults [2]. Furthermore, giant hepatic hemangioma coexistent with diffuse hepatic 
hemangiomatosis is even more uncommon, although an association exists between hemangiomatosis 
and giant hepatic hemangiomas [3]. Here, we describe a pathologically proven giant hepatic 
hemangioma coexistent with diffuse hepatic hemangiomatosis that presented as intrahepatic portal 
vein obstruction with subsequent hepatic segmental atrophy and extrahepatic portal vein thrombosis.
Case Report
A 78-year-old man was admitted to our hospital with a two-week history of abdominal pain and 
A combination of giant hepatic hemangioma and diffuse hemangiomatosis is extremely rare in 
adults. Even when they are large, hemangiomas are soft and rarely compress adjacent structures. 
A 78-year-old man presented with abdominal pain and distension. Ultrasonography, computed 
tomography, and magnetic resonance imaging demonstrated a large expansile mass replacing 
the medial segment and caudate lobe with diffusely scattered nodules in the entire liver. The large 
hilar mass contained a central nonenhancing area and had a mass effect, leading to left portal 
vein occlusion. The image findings also revealed two unprecedented findings: left lateral segmental 
atrophy of the liver and recent portomesenteric vein thrombosis. The hepatic lesions were 
confirmed with hemangiomas by ultrasonography-guided biopsy. We diagnosed intrahepatic portal 
vein obstruction caused by a mass effect of giant hepatic hemangioma coexistent with diffuse 
hemangiomatosis, resulting in hepatic segmental atrophy and extrahepatic portal vein thrombosis.
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distension. The patient had been taking medicine for hypertension 
but denied a prior history of using other drugs. The laboratory 
findings revealed abnormalities such as decreased hemoglobin (11.4 
g/dL), and slightly elevated levels of serum alanine aminotransferase 
(41 IU/L), aspartate aminotransferase (41 IU/L), and alkaline 
phosphatase (161 IU/L). Alpha-fetoprotein was not increased and 
the Child-Pugh score classification was A; total bilirubin, serum 
albumin, and platelet count were within normal limits, there was no 
evidence of hepatic encephalopathy, and a small amount of ascites 
was observed on the initial abdominal computed tomography (CT) 
scan. On physical examination, the patient showed no hemangiomas 
on the skin.
At the first appearance of symptoms, an initial abdominal CT 
scan was performed at an outside clinic. The CT demonstrated 
diffuse hepatic nodules involving the entire liver and a large 
heterogeneous mass replacing the left medial segment and caudate 
lobe (Fig. 1). Because ascites, colonic edema, and gallbladder edema 
accompanied the diffuse hepatic lesions, diffuse hepatocellular 
carcinoma was suggested, and the patient underwent chemotherapy 
(sorafenib, 400 mg/day) for 12 days. He complained of a newly 
developed headache and general weakness, so chemotherapy was 
stopped immediately. However, he continued to suffer from the 
abdominal pain and distension that he had previously reported. Two 
months after the symptoms had begun, ultrasonography (US; iU22 
system, Philips, Bothell, WA, USA), CT (Somatom AS+, Siemens, 
Forchhein, Germany), and magnetic resonance imaging (MRI; 
Magnetom Skyra 3.0T, Siemens, Erlangen, Germany) were performed 
for a further work-up.
On abdominal US, a large heterogeneous hyperechoic mass with 
a central hypoechoic portion was observed in the central hilus of 
the liver and the outer margin of the hyperechoic mass was not well 
defined (Fig. 2A). Numerous discrete and coalescent hyperechoic 
nodules, relative to the normal liver parenchyma, were scattered 
throughout the liver (Fig. 2B). In addition, hyperechoic bland portal 
vein thrombosis and dilated hepatic arteries were noted at the 
hepatic hilus level (Fig. 2C).
Both initial and follow-up abdominal contrast-enhanced CT 
images demonstrated heterogeneous nodular enhancement in the 
entire liver with a large central mass containing an unenhanced, 
central, markedly hypodense area in the medial segment and 
caudate lobe. It also showed peripheral punctate calcifications in the 
central hypodense area, suggesting phleboliths (Figs. 1, 2D).
On T2-weighted MR images, numerous nodular hyperintense 
lesions were scattered throughout the liver. A central markedly 
hyperintense area was suspected to be a different histologic region, 
compared with the adjacent nodular lesions (Fig. 2E). Dynamic 
MR axial images revealed discontinuous nodular enhancement 
with gradually filled nodules that turned more homogeneous, 
but with some remaining unfilled portions. These findings were 
consistent with diffuse hepatic hemangiomatosis. The central 
unenhanced, hypointense area did not change without enhancement, 
corresponding to a degenerative change of a giant hemangioma. 
Similar to the US images, there was no distinct margin between the 
giant hemangioma and the adjacent hemangiomatosis (Fig. 2F, G). 
CT and MRI images clearly revealed the mass effect of the central 
hepatic lesion. The medial segment and caudate lobe were replaced 
by a large mass with an anteriorly bulging appearance. Furthermore, 
the horizontal and umbilical portions of the left portal vein could 
not be traced, suggesting left portal vein occlusion by central 
mass compression (Figs. 1, 2D). The mass also compressed the 
intrahepatic inferior vena cava (not shown in figure). 
Further, they showed two unique findings consequential of the 
mass effect. First, left lateral segmental atrophy of the liver was 
evident, suggesting a result of left portal vein occlusion. Second, 
similar to the US findings, portomesenteric vein bland thrombosis 
was observed from the superior mesenteric vein to the main portal 
Fig. 1. Initial abdominal computed tomography (CT) of diffuse 
hepatic hemangiomatosis and coexistent giant cavernous 
hemangioma in a 78-year-old man. Axial contrast-enhanced CT 
image during the arterial phase shows heterogeneous nodular 
enhancement in both hemilivers and a contour-bulging mass with 
a central markedly low density area involving the caudate lobe. 
The expansile mass (arrowheads) protruded anteriorly, and the 
horizontal portion of the left portal vein was invisible, suggesting 
left portal vein occlusion by the mass effect of the caudate lobe 
lesion. The umbilical portion of the left portal vein was also invisible 
along the fissure for ligamentum teres (white arrow). Ascites in 
the right subphrenic space and dilated hepatic artery (long arrows) 
measuring 10-mm can be noted. There was no portomesenteric vein 
thrombosis (not shown).Giant hepatic hemangioma with diffuse hemangiomatosis
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Fig. 2. Follow-up ultrasonography (US), computed tomography (CT), and 
magnetic resonance imaging (MRI) in the same patient 2 months after 
symptoms had begun. 
A, B. Abdominal US images show a large, heterogeneous hyperechoic 
mass with a central hypoechoic lesion (star) in the center of the liver, and a 
continuous hyperechoic area with a poorly defined margin of the mass (A). 
Numerous additional discrete and coalescent hyperechoic nodules (arrows), 
compared with normal parenchyma (asterisk), are scattered throughout the 
entire liver (B). C. US image in the hepatic hilum area shows hyperechoic bland 
thrombus (white arrows) along the main portal vein and dilated common 
hepatic artery (black arrows). D. Coronal contrast-enhanced CT image during 
the venous phase demonstrates heterogeneous nodular enhancement in 
both hemilivers. The large mass containing a central unenhanced, markedly 
hypodense area (star) replaces the medial segment with a bulging contour. 
There is portomesenteric bland thrombosis from the superior mesenteric vein 
to the main portal vein, part of the right portal vein (white arrows). Furthermore, the volume of the left lateral segment of the liver (asterisk) 
was decreased, suggesting hepatic lobar atrophy. It also shows calcification (black arrowheads) in the central large mass. The remaining 
ascites should be noted in both subphrenic spaces. E. T2-weighted MR image using half-Fourier single-shot turbo spin echo sequence (TR/
TE infinite/103 ms, flip angle 107°) demonstrates diffusely scattered nodular lesions with hyperintensity relative to the unaffected liver 
parenchyma (segment 7). This also shows marked hyperintensity of the central area (star). 
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vein, and in part of the right portal vein (Fig. 2D). In addition, 
ascites, colonic edema, and gallbladder edema appeared consistent 
with the findings of an earlier CT performed at an outside clinic (not 
shown in figure), suggesting more associated evidence of portal vein 
obstruction.
To rule out other hepatic malignant tumors, an US-guided gun 
biopsy was performed in the right hemiliver using an 18-gauge core 
needle (Acecut, TSK Laboratory, Tochigi, Japan). The histological 
analysis revealed a typical cavernous hemangioma that had 
irregularly dilated nonanastomotic vascular spaces lined with flat 
endothelial cells alternating with normal hepatic parenchyma, 
without cellular atypia (Fig. 2H, I). During a further work-
up, we obtained previous outside abdominal US images taken 
8 years earlier, and they showed diffuse and inhomogeneous 
echogenicity throughout the liver, suggesting pre-existing 
diffuse hemangiomatosis (Fig. 3). Hence, we finally diagnosed 
the patient with intrahepatic left portal vein obstruction caused 
by a giant hepatic hemangioma coexistent with diffuse hepatic 
hemangiomatosis, resulting in development of left hepatic lobar 
atrophy and extrahepatic portal vein thrombosis.
There were no significant complications (high-output heart 
failure, liver failure, or thrombocytopenia) caused by the hepatic 
hemangiomatosis. Surgery was not performed, and the patient 
was observed with follow-up. Over a 9-month follow-up period, 
abdominal discomfort was reduced and quality of life improved. The 
blood chemistry, including liver enzymes, improved to within normal 
limits.
Fig. 2. F, G. Serial gadolinium-enhanced T1-weighted MR axial images using a fat-suppressed, 3-dimensional volumetric interpolated breath-
hold examination sequence (TR/TE 3.5/1.5 ms, flip angle 9°) show discontinuous nodular enhancement on the arterial phase (F) and 
gradual fill-in enhancing nodules turning more homogeneous but some remaining unfilled portions during the delayed phase (G), consistent 
with diffuse hepatic hemangiomatosis. The central markedly hypointense area (star) did not change without enhancement, corresponding 
to a degenerative change of the giant hemangioma. There was no distinct margin between giant hemangioma and adjacent diffuse 
hemangiomatosis. H, I. Histological findings reveal large, dilated vessels of varying size lined by flattened endothelium and arranged in a 
haphazard pattern (H; H&E, ×200), and they are separated by fibrous septa of various thicknesses (I; Masson’s trichrome stain, ×100).
H I
G FGiant hepatic hemangioma with diffuse hemangiomatosis
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Discussion
Cavernous hemangiomas are the most common type of hepatic 
benign tumors and are most frequently observed in women between 
the third and fifth decade of life [2]. These tumors are soft and 
usually do not compress or invade adjacent structures. However, they 
may cause a mass effect when they attain substantial dimensions 
or have a modified internal component, such as a thrombosis or 
hemorrhage, transforming the lesion into a firm solid mass [1,4]. 
Some reports have described a mass effect on the bile duct, inferior 
vena cava, or portal vein in giant hepatic hemangioma (>4 cm in 
diameter) [1,4-6]. These mass effects manifest as displacement or 
compression of the intrahepatic vein or inferior vena cava without 
associated complications. In three cases, portal vein obstruction 
was described, two of which presented on imaging as a perfusion 
abnormality in the adjacent liver parenchyma [1]. In the other case, 
a significant portal vein obstruction was observed with a cavernous 
transformation [5]. However, none of them showed portal vein 
thrombosis or hepatic lobar atrophy as sequential findings of portal 
vein obstruction. 
Hepatic lobar atrophy is mostly caused by a hepatic hilar malignant 
tumor or iatrogenic damage of the biliary duct and portal vein, and 
there is a strong correlation between lobar atrophy and ipsilateral 
portal vein obstruction [7]. In our case, the giant hemangioma was 
located in the medial segment and caudate lobe of the liver and 
protruded anteriorly. Therefore, this compressed the horizontal 
portion of the left portal vein and had a possibility of long-standing 
compression due to benignness of the mass. Therefore, we suggest 
that the hilar giant hemangioma caused the left portal vein 
obstruction, leading to ipsilateral hepatic lobar atrophy. 
Sorafenib (BAY 43-9006, Nexavar; Bayer, Leverkusen, Germany) is 
an oral multikinase inhibitor with antiangiogenic and antiproliferative 
effects. This could exert a beneficial effect on portal vein thrombosis 
by the inhibition of the vascular endothelial growth factor receptor 
pathway, which may play a pivotal role in portal vein thrombosis 
onset and evolution, as well as in hepatocellular carcinoma 
angiogenesis [8]. A portal vein thrombosis is found in 0.18% of 
patients with hepatocellular carcinoma when using sorafenib [9]. 
This is a much lower incidence than that of native hepatocellular 
carcinoma (neoplastic thrombosis, 6.5%-44%; bland thrombosis, 
42%) [10], and could show that sorafenib actually reduces the risk 
of development of portal vein thrombosis. Thus, although portal 
vein thrombosis was found after sorafenib monotherapy in our 
case, there is a low possibility of chemotherapy-induced portal vein 
thrombosis. Furthermore, ascites, colonic congestion, and gallbladder 
edema were already present in the initial abdominal CT without 
evidence for other causes such as liver cirrhosis or inflammatory 
lesions. Therefore, we came to the conclusion that all of the imaging 
findings, including portomesenteric vein thrombosis, were caused 
by intrahepatic portal vein obstruction, resulting from the mass 
effect of the giant hepatic hemangioma. Prothrombotic states, 
local factor causing vessel wall injury, venous stasis contribute to 
mesenteric vein thrombosis. The latter is more frequently associated 
with combined mesenteric and portal vein thrombosis, whereas 
the former manifests as isolated mesenteric vein thrombosis [11]. 
Because superior mesenteric vein thrombosis was combined with 
portal vein thrombosis in our case, we suggested that this was also 
a sequential finding of the intrahepatic portal vein obstruction.
Our case showed typical imaging findings for giant cavernous 
hemangioma―[HC1] early discontinuous peripheral nodular 
enhancement with progressive centripetal enhancement to uniform 
fill-in but a persistent, markedly hypodense central area in the 
medial segment and caudate lobe of the liver. Some studies have 
demonstrated that marked hyperintensity of the central area on a T2-
weighted image corresponds to hypocellular myxoid tissue and may 
represent an intermediate stage in the evolution from thrombosis 
to the final well-formed fibrous scar [1,4]. Our case also showed a 
central area with marked hyperintensity on the T2-weighted image, 
suggesting the possibility of myxoid change. Based on the above-
mentioned references, we assumed that hemorrhage might have 
occurred in the central area of the giant hemangioma just before 
the onset of symptoms and that this aggravated the mass effect by 
increasing the volume and making the tumor firmer. Accordingly, 
this probably evoked development of recent portal vein thrombosis, 
Fig. 3. Previous abdominal ultrasonography of the same patient, 
taken 8 years before diagnosis of diffuse hepatic hemangio-
matosis and coexistent giant cavernous hemangioma. Diffuse and 
inhomogeneous echogenicity is located in the center of the liver.Bo Reum Yoo, et al.
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as well as ascites, colonic congestion, and gallbladder edema, which 
were acute manifestations of the portal vein obstruction.
Diffuse hepatic hemangiomatosis usually presents in infancy, 
with Rendu-Osler-Weber disease or skeletal hemangiomatosis. 
Isolated diffuse hepatic hemangiomatosis without extrahepatic 
lesions is extremely rare in adults [2]. Jhaveri et al. [3] argued for 
a significant association between giant hepatic hemangioma and 
hepatic hemangiomatosis. They found a hemangiomatosis pattern 
adjacent to the giant hemangioma in 18 of 41 patients (44%) 
with giant cavernous hemangiomas (>8 cm in diameter). In most 
cases, hemangiomatosis involved the adjacent margin of the giant 
hemangioma, without normal liver tissue separating them. The 
enhancement pattern of hepatic hemangiomatosis is similar to 
those of common hepatic hemangiomas. Our case showed multiple 
small discrete and coalescent nodules with a uniformly filled-
in enhancement pattern in both hemilivers without a definitive 
separation from the giant hemangioma. They also described US 
findings of hemangiomatosis as heterogeneous echo patterns 
with multiple discrete or small coalescent hypoechoic nodules on 
a hyperechoic background [3]. In our patient, the US findings were 
somewhat different from those of previous reports and showed 
mainly hyperechoic nodules with confluent to hyperechoic giant 
hepatic hemangioma, containing a markedly hypoechoic central 
area. Hepatic artery dilatation can be seen in patients with diffuse 
hepatic hemangioma and giant hepatic hemangioma [3]. Our case 
also showed diffuse dilatation of the common hepatic artery and its 
branches.
Hepatic angiosarcoma can mimic diffuse hepatic hemangiomatosis 
or giant hemangioma because this shows the image findings of 
an increased signal on the T2-weighted image, heterogeneous 
centripetal enhancement, and occasionally a central nonenhancing 
hypodense area, similar to that of giant cavernous hemangioma. 
However, this is rapidly progressive vascular tumor and most 
patients die within a year of diagnosis [12]. In our case, the hepatic 
lesions already existed 8 years earlier and were pathologically 
proven to be hemangiomas, so we could exclude angiosarcoma 
from the differential diagnosis.
In conclusion, giant hepatic hemangioma can cause significant 
portal vein obstruction by its mass effect. This, in turn, can cause 
hepatic lobar atrophy and portal vein thrombosis. Despite its 
rarity and these atypical features, a diagnosis of diffuse hepatic 
hemangioma coexistent with giant hepatic hemangioma in adults 
can be suggested based on the distinctive CT, MR, and US findings.
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